Chronic wounds can be difficult to heal and are often accompanied by pain and discomfort. Multiple skin substitutes or Cellularized/Tissue based skin Products (CTPs) have been used to facilitate closure of complex wounds. Allografts from cadaveric sources have been a viable option in achieving such closure. However, early assessment of graft incorporation has been difficult clinically, often with delayed evidence of failure. Visual cues to assess graft integrity have been limited and remain largely superficial at the skin surface. Furthermore, currently used optical imaging techniques can only penetrate a few millimeters deep into tissue. Ultrasound (US) imaging offers a potential solution to address this limitation.
There are several wound treatment modalities. Standard wound care elements include serial debridement, compression therapy, judicious use of various wound dressings to control moisture balance, along with antimicrobial efforts to optimize the wound bed for successful healing. CTPs or bioengineered skin grafts made of synthetic and/or biological materials are often used as aids to promote wound closure and restore skin function. The allograft skin substitutes provide a scaffold to the open wound defect. This scaffold will then become colonized by host immune cells as the healing cascade progresses. Clinicians often refer to the process of graft integration with the recipient area as “taking”. Healthy host cells infiltrate the allograft matrix. These cells then differentiate into regenerated tissue ultimately integrating with surrounding healthy host tissue in a seamless fashion. Allograft take is typically dependent on the integrity of a healthy granular host wound base. A negative immune response, infection, excessive exudation, and compromised hemostasis can all endanger the survival of the allograft. Obstruction of adherence to granulating tissue and penetration of neo-capillaries can occur. Currently, clinicians rely on clinical experience and visual cues such as graft color, odor, texture, edema, drainage and necrosis to monitor the graft and the underlying wound health. However, visual inspection is limited to the skin surface whereas underlined edema and graft detachment can go unnoticed. Furthermore, studies have shown extensive heterogeneity in wound evaluations between different healthcare professionals. This underscores the necessity for a more objective wound assessment system that avoids this observational variation.
The use of ultrasound (US) to monitor wound healing and allograft integration has been evaluated to develop systems and techniques for improving monitoring, assessing and treating of wounds. A commercially available dual-mode (ultrasound and photoacoustic) scanner was employed which operates only in US mode. We compared the reported wound size from the clinic to the measured size using US in 45 patients. Two patients from this cohort received an allogenic skin graft and underwent multiple US scans over a 110-day period. All the data was processed by two independent analysts and one of them was blinded to the study. We measured change in US intensity and wound contraction as a function of time. The results show a strong correlation (R2=0.81, p<0.0001) between clinically and US measured wound sizes. Wound contraction greater than 91% was seen in both patients after skin grafting. An inverse relationship between wound size and US intensity (R2=0.77, p<0.0001) showed that the echogenicity of the wound bed increases as healthy cells infiltrate the allograft matrix regenerating and leading to healthy tissue and reepithelization. This work shows that US can be used to measure wound size and visualize tissue regeneration during the healing process.
In one particular aspect, a method is provided for treating a skin wound. In accordance with the method, an ultrasound image is obtained of a skin wound on a patient. The ultrasound image is processed to extract information that is correlated to a degree of wound healing. The degree of wound healing is assessed based at least in part on the extracted information. The skin wound is treated based at least in part based on the assessed degree of wound healing.
In accordance with another aspect, the extracted information is a measure of intensity of the ultrasound image.
In accordance with another aspect, the measure of intensity is inversely correlated with wound size.
In accordance with another aspect, the measure of intensity is a mean gray scale value of the ultrasound image.
In accordance with another aspect, treating the skin wound includes performing a skin graft.
In accordance with another aspect, the method further includes monitoring the treatment over time by obtaining and processing additional ultrasound images at subsequent times.
In accordance with another aspect, the method further includes determining that the skin wound is healing if the measure of intensity exacted from the additional ultrasound images increases over time.
In accordance with another aspect, the method further includes predicting wound deterioration due to tissue loss based on the monitoring
In accordance with another aspect, a method is provided for monitoring treatment of a skin wound. In accordance with the method, an ultrasound image is obtained of a skin wound on a patient. The ultrasound image is processed to extract information that is reflective of wound size. A degree of wound healing is assessed based at least in part on the extracted information. The skin wound is treated based at least in part based on the assessed degree of wound healing. The treatment is monitored over time by obtaining and processing additional ultrasound images at subsequent times.
In accordance with another aspect the extracted information that is reflective of wound size is a measure of intensity of the ultrasound image, the measure of intensity being inversely correlated with wound size.
In accordance with another aspect, the method further includes modifying the treatment of the skin wound or performing an additional treatment of the skin wound based on the monitoring.
This Summary is provided to introduce a selection of concepts in a simplified form. The concepts are further described in the Detailed Description section. Elements or steps other than those described in this Summary are possible, and no element or step is necessarily required. This Summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended for use as an aid in determining the scope of the claimed subject matter. The claimed subject matter is not limited to implementations that solve any or all disadvantages noted in any part of this disclosure.
Ultrasound (US) imaging is a unique imaging modality that addresses the aforementioned limitations of other imaging modalities. It is a quick, inexpensive, non-radiative, non-invasive, and point-of-care imaging modality that can look deep into soft tissue (up to 10 cm). (Ng and Swanevelder 2011, Szabo and Lewin 2013) The use of ultrasound as a therapeutic tool to aid debridement and promote healing has been widely reported but there are very few reports of US imaging being used to monitor wound healing. (Driver and Fabbi 2010, Ennis, et al. 2011, Kavros, et al. 2007) A recent small case series showed that US, doppler, and elastography could be used to determine wound morphology, biomechanics and proximity to other anatomical structures like bone and tendon. (Henshaw, et al. 2020) Another case study in a 46-year old female with a stage IV sacral pressure ulcer showed that multiple two-dimensional US images could be reconstructed for three-dimensional visualization of the ulcer. (Yabunaka, et al. 2015) Photoacoustic imaging and high-resolution harmonic US has also been used to stage and track healing of pressure ulcers and burn wounds in animal models. (Gnyawali, et al. 2015, Hariri, et al. 2019) Although these studies depict the advantages of US imaging like deeper imaging and elastography, a longitudinal human clinical study monitoring wound healing has not yet been reported. The ability to monitor a skin graft as it integrates would have high clinical significance and allow clinicians to make more informed therapeutic decisions. This work aims to evaluate the use of US to monitor wound healing and allograft integration.
In this analysis 45 patients diagnosed with chronic foot wounds were scanned using ultrasound. Currently, wounds are sized by eye using a wound ruler as reference. Although more advanced sizing protocols using high-definition cameras using complex edge detection and neural networks have been reported, their limited penetration into tissue makes depth measurements difficult. Furthermore, wounds may prematurely contract at the surface level only ahead of a voluminous deeper cavity defect. This dimension is often neglected though it may further explain aberrant wound healing delays or cause of wound deterioration. The ability of US to non-invasively image under the skin surface make it an ideal imaging modality to solve such limitations. It will be demonstrated below (
Furthermore, we show that US intensity is a marker of tissue regeneration (
One limitation is that wounds above 4 cm in width are consistently undersized. This is because the US transducer used in this study has 128-elements each measuring 3.5 mm long with a pitch of 0.3 mm, giving it a lateral field of view of ˜4 cm. Using a bigger transducer with more sensing elements or using a tomographic system can solve this issue.
As further described below, we scanned 2 patients (referred as Patient A and B) who received allogenic skin grafts as part of normal wound treatment. Tissue loss or edema accumulation results in hypoechoic regions on US images. On the other hand, scar tissue and edema reduction through use of compression modalities results in hyperechoic regions.20 Patients have unique soft tissue density and collagen arrangements giving them unique baseline acoustic properties. It is important to measure healthy tissue US intensity separately for each case to distinguish between diseased, healthy, and scar tissue. With skin grafts, the ideal outcome is to restore anatomical continuity along with functionality while minimizing scarring. US imaging is an effective tool to visualize tissue regeneration because US intensity increases as the wound heals. We showed the ability to define whether a wound was healed using the US intensity of the wound bed (
Sometimes wounds deteriorate secondary into a deeper unhealed voluminous defect. This defect often collects fluid and may evolve into a seroma or an abscess. Such a defect is particularly difficult to predict and visualize with current methods at the bedside. Therefore, visual clinical cues such as erythema, swelling, fluctuance and/or presence of pain can be used to predict tissue health under the skin. We show that US imaging is especially effective in providing insight into deeper wound elements by predicting tissue loss as early as Day 1 (
Also demonstrated below is the ability to monitor wound health after skin grafting. Once skin grafted, the wound surface is completely obscured from the clinician's view, and the top layer of then graft often dies due to lack of blood flow. It can take weeks for doctors to diagnose a non-taking skin graft whereas we show that we can visualize tissue regeneration longitudinally. This is visible in Patient B who was grafted on day 49, followed by a period of tissue loss after skin grafting and then a rapid healing. It is key to note that different areas of the wound responded differently to skin grafting. Site iii responded before sites I and ii (
The ability of US to predict tissue loss is seen in patient B (
The lack of healing in Patient A initiated the use of a second allogenic skin graft. This lack of healing is usually diagnosed by years of experience, but longitudinal US imaging can quantify it objectively (
Additional details and results concerning this study will be presented below.
Patient inclusion criteria were as follows: (i) patients with ulcers not more than 15 cm2 in area. ii) patients 18 years or older and be able to provide consent. Exclusion criteria included i) Patients with a blood-borne pathogen ii) patients with other lesions (e.g., Melanomas) at the wound site. iii) patients with orthopedic implants patients presenting with wounds between digits or in the pubic region; 63 patients (65 wounds) were recruited for this study. Table 1 describes the patient demographic distribution. All patients were imaged.
Two patients (Patients A and B) who received allogenic skin grafts underwent multiple follow-up scans over a period of 110 days. Patient A was a 77-year-old non-diabetic female with a history of hypothyroidism. Patient A presented with an open, chronic, post-operative left knee wound with tendon involvement and chronic venous hypertension on both sides. Patient A was first scanned 103 days after presentation followed by 13 follow-up scans over a 110-day period. Patient B was a 33-year-old non-diabetic male with a history of renal transplant. Patient B presented with a left, anterior, lower limb, posttraumatic ulcer with chronic venous hypertension on the left side. Patient B was first scanned 33-days after presentation followed by 10 follow-up scans over a 106-day period.
This study did not involve any additional visits and was performed during a regularly scheduled wound care visit. The frequency of visit was independently decided by the wound specialist (CA) depending on the patient's needs. The wound site was prepared by removing any dressings and cleaning with sterile saline prior to scanning. Neighboring tissue was further cleaned using alcohol swabs to prevent infection. A photograph with a wound ruler was also taken to correctly size the wound surface. To prevent cross contamination and infections, we used a new sterile CIV-Flex™ transducer cover for every scan (#921191 from AliMed Inc., Dedham, MA, USA).
We used a commercially available LED-based photoacoustic/ultrasound imaging system (AcousticX from CYBERDYNE Inc. (Tsukuba, Japan)). (Hariri, et al. 2018) In this study, we only used the ultrasound mode. The ultrasound transducer has 128 linearly arranged elements operating with a central frequency of 7 MHz, bandwidth of 80.9% and field of view of 4 cm. Sterile US gel (Aquasonic 100, Parker Laboratories Inc., Fairfield, NJ, USA) and a custom hydrophobic gel pad from CYBERDYNE INC. (Tsukuba, Japan) was used for US coupling between the transducer and skin surface. All US images were acquired at 30 frames per second.
Wounds smaller than 5 cm in length (Patient A) were scanned in a single sweep from inferior healthy tissue over the wound to superior healthy tissue. From these scans, we selected representative frames for inferior healthy tissue, two wound sites (site I and ii), and superior healthy tissue. For large wounds (Patient B), we selected three wounded sites at discrete distances from the inferior wound edge and tracked wound progression over time.
All US frames were reconstructed and visualized using the AcousticX photoacoustic imaging system developed by CYBERDYNE Inc. (Tsukuba, Japan) version 2.00.10. B-mode, coronal cross-section images were exported as 8-bit gray scale images. The images were further processed to measure wound width, area, and US intensity using Fiji an ImageJ extension version 2.1.0/1.53c. (Schindelin, et al. 2012) Data was plotted using Prism9 version 9.0.0. All measurements were made using custom region of interest (ROI) analysis for individual frames. Drawing ROIs by hand can be very subjective. Hence, all image quantification was independently confirmed by two analysts (YM and JT). JT was blinded to the study and only received B-mode US images to analyze the data.
To corroborate our method with the current gold standard eye measurements we compared reported wound size with size measured with US imaging. The reported wound size was provided by CA and his nursing team and was recorded as part of standard care. The wound width under US was measured using custom ROI analysis to outline the wound on a single frame. Wound width was defined as the widest region within the wound ROI.
We quantified changes in US intensity over time in a constant ROI. A custom ROI (outline of wound site) was drawn for Patient A and B on day 1 and the US intensity within that ROI was tracked over time. Maintaining a constant ROI allows us to quantify tissue regeneration as the graft integrates into the wound bed. To further compare US intensity between wounded and healthy tissue, a dynamic baseline US intensity for healthy tissue was measured. We measured the mean gray value and its standard deviation (0.5 cm×0.5 cm ROI) in two frames representing inferior and superior healthy tissue, for each time point. The healthy window was defined within one standard deviation of the dynamic baseline. US intensities falling under and over this window were considered as wound and scar tissue respectively.
Finally, we monitored change in wound area under the skin graft. Custom ROIs were drawn for individual sites at each imaging time point. An area was considered to be a wound if its US intensity was significantly below the healthy window defined above.
A Bland-Altman analysis was used to look for bias between clinically reported wound (gold standard) and US measured wound width. A mean bias more that 0.06 cm would be considered clinically significant as the lateral resolution of the US transducer ranges from 0.05-0.06 cm.
To reduce the subjective nature of ROI-based analysis two independent analysts, YM and JT processed all the images. JT was blinded to the study. A Bland-Altman analysis was used to look for systemic bias between two independent analysis of the same images. For US intensity measurements a mean bias above 17 gray scale values (standard deviation in healthy tissue) would be considered clinically significant. For wound area measurements, a mean bias greater than 5% of the largest wound size would be considered clinically significant.
Of the cohort of 63 patients with 65 wound sites, 20 wounds could not be sized with US: 15 wounds did not have a reported wound size from the clinic and were excluded; five wounds were located in regions with high curvature such as the lateral side of the toe or ankle, which makes US coupling difficult in these regions with a linear array transducer. Hence, 45 wounds were used to compare reported wound size with the US measured size.
Patient A
Patient A had a left knee ulceration who underwent 13 US scans over 110-day-scan. Patient A received a human cadaver-derived, acellular dermal matrix (AlloDerm, Lifecell, Branchburg, NJ) skin graft 28 days prior to the first scan. A second tissue matrix allograft composed of dehydrated human amnion/chorion membrane (EpiFix, MiMedx, Marietta GA) was used 75-days after the first scan.
For Patient A, the dynamic baseline for healthy tissue was measured over 13 independent scans. (73.5±12.9 (unique for patient A)). Changes in US intensity over time for site i and ii showed that it took 90 days for site i and 96 days for site ii to achieve gray scale values similar to healthy tissue (
Patient B
Patient B was a 33-year-old male with an anterior, lower left limb ulceration who underwent 10 US scans over a 106-day period. Patient B received a human cadaver-derived, acellular dermal matrix (AlloDerm, Lifecell, Branchburg, NJ) skin graft 49 days after the first scan. We monitored wound progression at three wound sites i, ii, and iii (inferior, medial, and superior, respectively).
In particular,
The average healthy gray value measured over 10 separate scans for Patient B was 90.4±21.5 (unique for patient B). All wound sites showed an increase in wound size and loss of US signal until skin grafting followed by a tissue regeneration and wound contraction period. Healthy control tissue remained unchanged over the same time period. Sites i and ii responded differently compared to site iii (
A plot of wound area vs. US intensity, shown in
All data quantification was done by two independent analysts (YM and JT). JT was blinded to the study while YM acquired and analyzed all the data. Bland-Altman analysis revealed no significant bias between the two analysts. For US intensity measurements, a mean bias of 4.12 gray values between the two analysts, rejected our null hypothesis of clinical significance above 17 gray values (standard deviation in healthy tissue). For wound area measurements, a mean bias of 0.10 cm2 (4.4% of largest measured wound size) rejected our null hypothesis of clinical significance above 5% of the largest measured area.
The fast, inexpensive, reliable, and pain free characteristics of point-of-care US imaging make it an ideal modality to monitor wound progression. Currently, wounds are sized by eye using a wound ruler as reference. Although more advanced sizing protocols using high definition cameras using complex edge detection and neural networks have been reported, their limited penetration into tissue makes depth measurements difficult. (Chino, et al. 2020, Malone, et al. 2020, Toygar, et al. 2020) Furthermore wounds may prematurely contract at the surface level only ahead of a voluminous deeper cavity defect. (Medina, et al. 2005) This dimension is often neglected though it may further explain aberrant wound healing delays or cause of wound deterioration. The ability of US to non-invasively image under the skin surface make it an ideal imaging modality to solve such limitations.
Tissue loss or edema accumulation results in hypoechoic regions on US images. (Ripollés, et al. 2013, Terslev, et al. 2003) On the other hand, scar tissue and edema reduction through use of compression modalities results in hyperechoic regions. (Ackerman, et al. 2019) Patients have unique soft tissue density and collagen arrangements giving them unique baseline acoustic properties. It is important to measure healthy tissue US intensity separately for each case to distinguish between diseased, healthy, and scar tissue. With skin grafts, the ideal outcome is to restore anatomical continuity along with functionality while minimizing scarring. US imaging is an effective tool to visualize tissue regeneration because US intensity increases as the wound heals. This phenomenon is clearly visible with both patients A and B.
Sometimes wounds deteriorate secondary to a deeper unhealed voluminous defect. This defect often collects fluid and may evolve into a seroma or an abscess. (Landis 2008) Such a defect is particularly difficult to predict and visualize with current methods at the bedside. Therefore, visual clinical cues such as erythema, swelling, fluctuance and/or presence of pain can be used to predict tissue health under the skin. (Ren, et al. 2020) Ultrasound imaging is especially effective in providing insight into deeper wound elements. The real time, high-resolution, high-depth penetration nature of ultrasound allows it to detect signs of edema and tissue loss before it is visible on the skin surface. The ability of US to predict tissue loss is seen in patient B (
Wound healing is an extremely complicated process that is affected by many variables such as age, local perfusion, moisture and patient compliance. (Guo and DiPietro 2010, Valencia, et al. 2001) Younger patients are more likely to heal faster than older patients. (Gould, et al. 2020) Comparing the healing rates between patient A (77-year old) and patient B (33-year-old) in
In summary, ultrasound imaging is a valuable tool to study skin graft integration used for chronic wound treatment. We first showed that wound width measurements made by US imaging are strongly correlated to measurements made visually. Second, a thorough investigation into two patients (5 wound sites), both receiving allogenic skin grafts showed that wound contraction, healing, and skin graft integration could be monitored using wound area and US intensity. The loss of tissue and inflammation resulted in hypoechoic regions on the ultrasound which healed after skin graft placement and integration in both patients. Over 110 days, patient A showed up to 96% wound contraction whereas patient B showed up to 91.7% contraction over a similar period. During the healing process, US intensities recovered into the healthy tissue window showing soft tissue regeneration under the skin graft.
This application is a National Phase in the United States of PCT/US2022/012433, filed Jan. 14, 2022, which claims the benefit of U.S. Provisional Application No. 63/137,275, filed Jan. 14, 2021, the contents of both applications are incorporated herein by reference.
This invention was made with government support under AG065776 awarded by the National Institutes of Health. The government has certain rights in the invention.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2022/012433 | 1/14/2022 | WO |
Number | Date | Country | |
---|---|---|---|
63137275 | Jan 2021 | US |